Prof Dickinson
Abramson J et al. Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO. ASH 2025;Abstract 5519.
Andreadis C et al. Mosunetuzumab (mosun) or glofitamab (glofit) in combination with golcadomide (golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). ASH 2025;Abstract 66.
Budde E et al. Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (mosun-pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least one prior therapy. ASH 2025;Abstract 5509.
Gritti G et al. Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis. ASH 2025;Abstract 5510.
Karimi Y et al. Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma. ASH 2025;Abstract 5513.
Michot J-M et al. Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First results from part 1 of the phase 3 Olympia-3 study. ASH 2025;Abstract 65.
Sharman J et al. Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the phase II MorningSun study. ASH 2025;Abstract 62.
Vitolo U et al. Fixed-duration epcoritamab monotherapy induces high response and MRD negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3. ASH 2025;Abstract 63.
Dr Sehn
Bisneto JV et al. Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the phase 2 ELM-2 study. ASH 2025;Abstract 3588.
Budde E et al. Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal phase II study. ASH 2025;Abstract 5352.
Burke JM et al. Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study. ASH 2025;Abstract 228.
Falchi L et al. Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial. ASH 2025;Abstract 463.
Falchi L et al. Primary phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. ASH 2025;Abstract 466.
Leslie L et al. Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7. ASH 2025;Abstract 465.
Olszewski A et al. Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter phase 2 trial. ASH 2025;Abstract 1003.
Phillips T et al. Interim analysis of the phase II study of glofitamab, lenalidomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. Response and safety outcomes after the completion of stage 1 of 2 enrollment. ASH 2025;Abstract 883.
Sano D et al. Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (mosun-len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the phase III CELESTIMO study. ASH 2025;Abstract 1800.
Wudhikarn K et al. Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the phase 3 Olympia-2 study. ASH 2025;Abstract 3600.